Why did Collegium Pharmaceutical (COLL) stock move recently?

On 7/22/2026, Collegium Pharmaceutical moved -3.2% — Collegium Pharmaceutical shares declined with the broader market and healthcare sector amid no company-specific news or filings on July 22. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Collegium Pharmaceutical (COLL) overvalued or fairly valued?

MarketChacha shows Collegium Pharmaceutical's valuation in context — a trailing P/E of about 19.5, a forward P/E of about 3.6, a price-to-book of about 2.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Collegium Pharmaceutical's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (4.49×) from reported figures — education, not a rating.

What is Collegium Pharmaceutical's revenue?

Collegium Pharmaceutical reported revenue of $780.6M for FY2025, with net profit of $62.9M, per official filings.

What is the share price of Collegium Pharmaceutical (COLL)?

Collegium Pharmaceutical last traded at $24.23 (+2.2% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Collegium Pharmaceutical

COLL · NYSE · Healthcare · United States

Snapshot

TickerCOLL

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees423

HeadquartersStoughton, United States

Websitewww.collegiumpharma.com

Filings tracked17

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Who owns it

Insiders1.1%
Institutions98.8%
Public & other0.0%

389 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.71%
Jupiter Topco LLC6.60%
Invesco Ltd.5.78%
Fuller & Thaler Asset Management Inc.5.02%
Principal Financial Group, Inc.5.01%
State Street Corporation4.70%
Massachusetts Financial Services Co.4.32%
Vanguard Capital Management LLC4.24%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion4.49×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend8.5% → 8.1%

Margin has held broadly steady over the period — stable profitability.

Return on equity20.8%

Latest ROE of 20.8% — capital is generating a healthy return.

Growth qualityrev 17% · PAT 14%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $224.9M · EPS 1.99

Est. earnings growth -2.4%

Next fiscal year

Rev $828.1M · EPS 6.77

Est. earnings growth -9.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$780.6M

Net margin

8.1%

ROE

20.8%

Revenue CAGR (2y)

+17.4%

Profit CAGR (2y)

+14.3%

EPS (FY2025)

1.73

Net profit (FY2025)

$62.9M

Ask MarketChacha about COLL

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 22, 2026
Collegium Pharmaceutical shares declined with the broader market and healthcare sector amid no company-specific news or filings on July 22.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$780.6M	$62.9M	1.73	8.1%	20.8%
FY2024	$631.4M	$69.2M	1.86	11.0%	30.2%
FY2023	$566.8M	$48.2M	1.29	8.5%	24.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$199.9M	$-15.1M	-0.46	-7.5%
2026Q1	$193.5M	$14.5M	0.40	7.5%
2025Q4	$205.4M	$17.0M	0.46	8.3%
2025Q3	$209.4M	$31.5M	0.84	15.0%
2025Q2	$188.0M	$12.0M	0.34	6.4%
2025Q1	$177.8M	$2.4M	0.07	1.4%
2024Q4	$181.9M	$12.5M	0.36	6.9%
2024Q3	$159.3M	$9.3M	0.27	5.9%
2024Q2	$145.3M	$19.6M	0.52	13.5%
2024Q1	$144.9M	$27.7M	0.71	19.1%
2023Q4	$149.7M	$31.9M	0.82	21.3%
2023Q3	$136.7M	$20.6M	0.53	15.1%
2023Q2	$135.5M	$13.0M	0.34	9.6%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Reg FD disclosure
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K/A — Exhibits
SEC6/30/2026
8-K — Shareholder vote results
SEC5/15/2026material
8-K — Completion of acquisition/disposition, Executive/director change, Reg FD disclosure, Exhibits
SEC5/12/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Executive/director change
SEC4/7/2026material
8-K — Material agreement, Reg FD disclosure, Exhibits
SEC3/19/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026
8-K — Reg FD disclosure, Exhibits
SEC1/8/2026material

2025

8-K — Material agreement, Termination of agreement, Unregistered equity sale, Reg FD disclosure, Exhibits
SEC12/30/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/7/2025material
10-Q filing
SEC8/7/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.